Abstract: The present disclosure discloses a device and a method for continuously producing catalysts based on low-temperature coprecipitation. The device mainly includes: a metal salt preparation kettle, a primary reaction kettle, a secondary reaction kettle, a precipitant preparation kettle, a circulating refrigeration system, an automatic control system, a non-aqueous solvent storage tank and a water storage tank. Independent preparation kettles are provided for rapid dissolution of the raw materials, and can be used to prepare the raw materials for the next batch during the reactions that are carried out in the primary and secondary reaction kettles; the circulating refrigeration system refrigerates the primary and secondary reaction kettles, and thus during the reaction, the low-temperature precipitant makes it possible to offset the precipitation reaction heat and the heat caused by the stirring in the primary reaction kettle, and improve the refrigeration efficiency of the primary reaction kettle.

Abstract: The present disclosure discloses a device and a method for continuously producing catalysts based on low-temperature coprecipitation. The device mainly includes: a metal salt preparation kettle, a primary reaction kettle, a secondary reaction kettle, a precipitant preparation kettle, a circulating refrigeration system, an automatic control system, a non-aqueous solvent storage tank and a water storage tank. Independent preparation kettles are provided for rapid dissolution of the raw materials, and can be used to prepare the raw materials for the next batch during the reactions that are carried out in the primary and secondary reaction kettles; the circulating refrigeration system refrigerates the primary and secondary reaction kettles, and thus during the reaction, the low-temperature precipitant makes it possible to offset the precipitation reaction heat and the heat caused by the stirring in the primary reaction kettle, and improve the refrigeration efficiency of the primary reaction kettle.

Abstract: The present invention provides a method of using indole-ketone or indolidone such as SU4312, SU5416, SU11248 (Sunitinib), or indirubin-3-oxime to treat a neurodegenerative disease or disorder such as Parkinson's disease which is associated with excessive neuronal Nitric Oxide Synthase (nNOS) activity.

Abstract: The present invention provides a method of using indole-ketone or indolidone to treat or prevent a neurodegenerative disease or disorder. In one embodiment, the neurodegenerative disease is Parkinson's disease. In another embodiment, the neurodegenerative disease or disorder is associated with excessive neuronal Nitric Oxide Synthase (nNOS) activity. Examples of indole-ketone include, but are not limited to, SU4312, SU5416, SU11248 (Sunitinib), and indirubin-3-oxime.

Abstract: Novel heterodimers of tetrahydroacridines and tetrahydroquinolinones are disclosed. The heterodimers are capable of acting as both acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. The heterodimers may be used to improve cognitive defects via treatment or prevention in both humans and non-humans.

Abstract: Novel heterodimers of tetrahydroacridines and tetrahydroquinolinones are disclosed. The heterodimers are capable of acting as both acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. The heterodimers may be used to improve cognitive defects via treatment or prevention in both humans and non-humans.

Abstract: The invention relates to dimeric compounds comprising two 5-amino-5,6,7,8-tetrahydroquinoline fragments joined together by a divalent linking group, processes for their preparation, intermediates for their preparation, pharmaceutical compositions containing such dimeric compounds and the use of such compounds as cholinesterase inhibitors and in the treatment of neurodegenerative diseases, such as Alzheimer's Disease and myasthenia gravis.

Abstract: The invention relates to dimeric compounds comprising two 5-amino-5,6,7,8-tetrahydroquinoline fragments joined together by a divalent linking group, processes for their preparation, intermediates for their preparation, pharmaceutical compositions containing such dimeric compounds and the use of such compounds as cholinesterase inhibitors and in the treatment of neurodegenerative diseases, such as Alzheimer's Disease and myasthenia gravis.